

STATEMENT OF
CHANGES IN BENEFICIAL OWNERSHIP

o Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol		6. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
BVF Partners, L.P.			Flamel Technologies, S.A. ("FLMLY")		<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(Last)	(First)	(Middle)	3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)	4. Statement for Month/Day/Year		
				August 2002		
227 West Monroe Street, Suite 4800						
(Street)						
Chicago	Illinois	60606			7. Individual or Joint/Group Filing (Check Applicable Line)	
(City)	(State)	(Zip)			<input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I — Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount				(A) or (D)
French Ordinary Shares represented by American Depositary Shares "Ordinary Shares"	8/02/02	P			1,500	A	\$1.2233	(1)	(1)(2)
Ordinary Shares	8/02/02	P			1,000	A	\$1.2233	(1)	(1)(3)
Ordinary Shares	8/02/02	P			2,000	A	\$1.2233	(1)	(1)(4)
Ordinary Shares	8/02/02	P			17,000	A	\$1.2396	(1)	(1)(2)
Ordinary Shares	8/02/02	P			11,000	A	\$1.2396	(1)	(1)(3)
Ordinary Shares	8/02/02	P			25,000	A	\$1.2396	(1)	(1)(4)
						2,628,500(5)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).

POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

FORM 4 (Continued)

Table II — Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date
7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Following Reported	10. Ownership Form of Derivative Securities	11. Nature of Indirect Beneficial					

Title	Amount or Number of Shares
-------	-------------------------------

Explanation of Responses:

- (1) The shares reported in this response are beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments L.L.C., a Delaware limited liability company ("Investments"). Mark N. Lampert is the sole shareholder and sole director of BVF, Inc., and is an officer of BVF, Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.
- (2) Shares beneficially owned by BVF, L.P.
- (3) Shares beneficially owned by BVF2, L.P.
- (4) Shares beneficially owned by Investments.
- (5) The amount of Ordinary Shares beneficially owned includes 1,251,000 Ordinary Shares and 1,377,500 Ordinary Shares beneficially owned pursuant to 665,000 Class A Warrants and 712,500 Class B Warrants.

BVF Partners L.P.

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

September 10, 2002

**Signature of Reporting Person

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FORM 4 (Continued)

1. Biotechnology Value Fund, L.P.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606
- BIOTECHNOLOGY VALUE FUND, L.P.
- By: BVF Partners L.P., its general partner
- By: BVF Inc., its general partner
- By: /s/ MARK N. LAMPERT
- September 10, 2002
- **Signature of Reporting Person
Authorized Signatory
- Date
2. Biotechnology Value Fund II, L.P.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606
- BIOTECHNOLOGY VALUE FUND II, L.P.
- By: BVF Partners L.P., its general partner
- By: BVF Inc., its general partner
- By: /s/ MARK N. LAMPERT
- September 10, 2002
- **Signature of Reporting Person
Authorized Signatory
- Date
3. BVF Investments, L.L.C.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606
- BVF INVESTMENTS, L.L.C.
- By: BVF Partners L.P., its manager
- By: BVF Inc., its general partner
- By: /s/ MARK N. LAMPERT
- September 10, 2002
- **Signature of Reporting Person
Authorized Signatory
- Date
4. BVF, Inc.
One Sansome Street, 31st Floor
San Francisco, California 94104
- BVF INC.
- By: /s/ MARK N. LAMPERT
- September 10, 2002
- **Signature of Reporting Person
Authorized Signatory
- Date
5. Mark N. Lampert
One Sansome Street, 31st Floor
San Francisco, California 94104
- By: /s/ MARK N. LAMPERT
- September 10, 2002
- **Signature of Reporting Person
Authorized Signatory
- Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.